新型A-Flux冠状静脉窦减压器使一名持续有症状患者的冠状动脉微血管功能恢复正常。
The Novel A-Flux Coronary Sinus Reducer Normalizes Coronary Microvascular Function in a Persistently Symptomatic Patient.
作者信息
Occhipinti Giovanni, Salazar-Rodriguez Anthony, Giannini Francesco, Puri Rishi, Abdul-Jawad Altisent Omar, Regueiro Ander, Freixa Xavier, Flores-Umanzor Eduardo, Sabaté Manel, Brugaletta Salvatore
机构信息
Hospital Clínic, Cardiovascular Clinic Institute, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
Division of Cardiology, IRCCS Ospedale Galeazzi-Sant'Ambrogio, Milan, Italy.
出版信息
JACC Case Rep. 2025 Mar 19;30(6 Pt 1):102962. doi: 10.1016/j.jaccas.2024.102962. Epub 2025 Jan 22.
Coronary microvascular dysfunction (CMD) contributes to persistent angina/anginal equivalent symptoms and is associated with adverse outcomes. Coronary sinus reduction (CSR) is a device-based therapy with the potential to improve outcomes by reducing symptom burden and improving coronary flow reserve. A patient with CMD underwent CSR with the next-generation A-Flux device.
冠状动脉微血管功能障碍（CMD）会导致持续性心绞痛/心绞痛等效症状，并与不良预后相关。冠状动脉窦减压（CSR）是一种基于装置的治疗方法，有可能通过减轻症状负担和改善冠状动脉血流储备来改善预后。一名患有CMD的患者使用下一代A-Flux装置接受了CSR治疗。
Zotero 插件